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Abstract 
There is growing appreciation that castration-recurrent prostate cancer (CR-CaP) is driven by the 
continued expression of androgen receptor (AR). AR activation in CR-CaP through various 
mechanisms, including AR overexpression, expression of AR splice variants or mutants, increased 
expression of co-regulator proteins, and by post-translational modification, allows for the induc-
tion of AR-regulated genes in response to very low levels of tissue-expressed, so-called intracrine 
androgens, resulting in pathways that mediate CaP proliferation, anti-apoptosis and oncogenic 
aggressiveness. The current review focuses on the role played by Src-family (SFK) and Ack1 
non-receptor tyrosine kinases in activating AR through direct phosphorylation, respectively, on 
tyrosines 534 or 267, and how these modifications facilitate progression to CR-CaP. The fact that 
SFK and Ack1 are central mediators for multiple growth factor receptor signaling pathways that 
become activated in CR-CaP, especially in the context of metastatic growth in the bone, has 
contributed to recent therapeutic trials using SFK/Ack1 inhibitors in monotherapy or in combi-
nation with antagonists of the AR activation axis. 
Key words: Src-family tyrosine kinases, Ack1, androgen receptor, prostate cancer, castra-
tion-recurrence. 
Introduction 
In 2013, 238,590 new cases of prostate cancer 
(CaP) are estimated to be identified, typically through 
increased levels of serum prostate specific antigen 
(PSA), digital rectal exams and pathologic analyses of 
biopsy samples. Roughly 12-13% of these cases will 
result in death (29,720 estimated in 2013), making it 
the second leading cause of cancer deaths in U.S. men 
(http://seer.cancer.gov/statfacts/html/prost.html). 
Since the initial description by Huggins and Hodges 
in 1941 [1] that CaP can be clinically reduced by cas-
tration, which causes deprivation of testicular andro-
gen, most treatment-naïve CaP cases have been 
treated with some combination of andro-
gen-deprivation therapy (ADT) plus surgical prosta-
tectomy or radio-ablation. This has resulted in high 
initial cure rates of early, localized disease and pallia-
tion of metastatic disease. However, the so-called le-
thal clinical phenotype of CaP relates to disease re-
currence following ADT, producing castra-
tion-recurrent (CR) metastatic disease that is found 
primarily in the bones and lymph nodes, and that 
responds poorly to standard chemotherapy and radi-
ation [2].  
CR-CaP: Dependence on AR signaling 
Most CR-CaP cases continue to express the an-
drogen receptor (AR) as well as significant androgen- 
and AR-driven genes such as PSA [3]. Indeed, CR-CaP 
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cases typically express increased levels of AR protein 
[4-6], sometimes attributable to AR gene amplification 
[7], and as well, increased levels of andro-
gen-responsive genes such as PSA and TMPRSS2 [8]. 
The notion that CR-CaP is AR-dependent is support-
ed by the recent clinical success of AR antagonists 
such as enzalutamide (MDV3100), which increases 
survival rates in CR-CaP patients but only for several 
months [9]. The ultimate failure of AR antagonists to 
produce durable cures has been associated with the 
generation of AR splice variants lacking the lig-
and-binding domain (LBD) [10] or a F876L mutation 
in the LBD [11, 12]. Less understandable, however, are 
enzalutamide-resistant cases that continue to express 
WT-AR; these may reflect that AR overexpression 
may convert AR antagonists to agonists [13]. In addi-
tion to AR activation by direct tyrosine phosphoryla-
tion by SFK and Ack1 kinases- which will be the focus 
of the current review, other studies have identified 
additional AR-related changes that may contribute to 
CR-CaP: i) AR mutations (primarily in the LBD) that 
increase binding for non-androgen agonists [14], ii) 
AR stabilization [15], iii) induction of AR 
co-regulators and iv) post-translational modification 
[14]. These CR-associated changes are thought to fa-
cilitate AR-driven tumor progression in response to 
the post-castration expression of low levels tissue an-
drogens [16].  
The notion that the sustained expression of 
AR-driven genes is required for CR-CaP generation is 
supported by several studies using mouse models of 
human CaP. For example, Yuan et al. [17] showed that 
growth of a cell line (R3) derived from CR-growths of 
the human CWR22 xenograft in castrates was sup-
pressed by the shRNA-mediated knockdown of AR, 
even though growth was not inhibited by the an-
ti-androgen, bicalutimide.  Campagno et al. [18] 
showed that intratumoral injections of AR-siRNA 
inhibited growth of LNCaP-C4-2 and CWR22Rv1 
cells, two CR-CaP lines.  Similar findings were 
demonstrated by Snoek et al. [19]  using a tetracy-
cline-regulated AR-shRNA in LNCaP-C4-2 cells and 
by Guo et al. [20]  using AR-shRNA in CWR22Rv1 
cells in castrates. An interesting twist on this concept 
comes from the study of Gan et al., [21], who showed 
that the ability of paclitaxel to inhibit the CR growth 
of CWR22Rv1 cells correlated with the downregula-
tion of AR caused by the expression of the PTEN tu-
mor suppressor and the nuclear accumulation of the 
AR suppressive transcription factor, FOXO1.  Thus, 
siRNA-mediated FOXO1 knockdown attenuated the 
inhibitory  effect of paclitaxel on AR-driven 
CR-promoting genes.  
 Several studies have demonstrated that andro-
gen-independent or CR-CaP cell lines, or CR-CaP 
tumor samples, have AR-driven gene expression sig-
natures that correlate with CR-CaP. Work from the 
Chinnaiyan and Brown labs [22, 23]  used 
AR-ChIP-chip or –ChIP-seq combined with gene ex-
pression analyses to identify AR cistrome genes in an 
androgen-independent LNCaP variant cell line whose 
expression pattern correlated with CR disease in hu-
mans.  For example, the study of Wang et al. [23] 
identified UBE2C, an AR-driven cell cycle regulated 
gene that overrides an M-phase checkpoint, as a 
marker of androgen-independent growth.  Interest-
ingly, by comparing the AR cistrome in CaP cells ex-
pressing full-length (FL) AR vs. a splice variant (V) of 
AR typically upregulated in abiraterone and enzalu-
tamide-resistant CR-CaP cells and tumors, Hu et al. 
[24] also identified UBE2C expression as a marker of 
specific for CR-CaP. A more recent study by Sharma 
et al. [25] analyzed the AR cistrome in human clinical 
CR-CaP samples, identifying a 16-gene signature with 
stronger correlation to CR-CaP than the aforemen-
tioned Chinnaiyan and Brown lab studies.  Im-
portantly, these and other studies identified tran-
scription factors such as GATA, OCT, PU1, TEF1 [26], 
FOXA1 [25], and the methyltransferase, EZH2 [27] as 
potential AR co-factors based on the proximity of 
their ChIP sites with those of AR.  Some transcrip-
tional co-factors, such as FOXA1, may only play a role 
in ligand-dependent AR function, since andro-
gen-independent AR binding sites in CR-CaP, whose 
sequences increasingly diverge from the classic an-
drogen responsive element (ARE: 
5'-GGA/TACANNNTGTTCT-3';  [28]), form under 
conditions of FOXA1-independence [29].  
CR-CaP: Increased Protein Tyrosine 
Phosphorylation, SFK and Ack1 activity  
The regulation of AR transcriptional activity by 
post-translational modifications such as phosphory-
lation, acetylation, sumoylation, ubiquitination and 
methylation, have been well described [30]. CR-CaP 
clinical samples exhibit increased relative protein ty-
rosine phosphorylation levels compared to levels in 
AD-CaP [31]. This correlates with increased activation 
levels on non-receptor tyrosine kinases [32] as well as 
receptor tyrosine kinases such as Met [33], c-Kit [34] 
and the EGFR family [35, 36]. However, the role of AR 
tyrosine phosphorylation may have been underap-
preciated because it is not induced by androgens such 
as dihydrotestosterone (DHT), whereas it is induced 
by EGF, heregulin, IL-6 or serum [20, 37, 38]. In con-
trast, androgens induce IGF-1R activity in prostate 
cancer progression [39].  
Although Src-family kinases are rarely mutated 
in human cancers [40, 41], there is growing apprecia-
tion that they play critical roles in cancer progression, Int. J. Biol. Sci. 2014, Vol. 10 
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especially associated with recurrent and metastatic 
disease [42-45], due to gene amplification [46], over-
expression or activation by post-translational modifi-
cation (reviewed in [47]).  Indeed, SFK play central 
roles in mediating oncogenic signaling downstream of 
many receptor tyrosine kinases, which are themselves 
activated in cancer by multiple mechanisms [48]. FGR 
is the only SFK member gene that has been shown to 
be amplified in prostate cancer, specifically, in 37% of 
hormone-refractory disease [49].  In  contrast, SFK 
members Src and Lyn are activated in CaP cell lines 
[50, 51] and tumor tissues [51], and Fyn is upregulated 
in primary prostate cancer vs. benign lesions [52], and 
even higher in metastases  as evidenced by in silico 
analysis of Oncomine studies (Figure 1).  Most SFK 
members share an autophosphorylation site (termed 
Y416 for chicken Src, Y419 for human Src) that is rec-
ognized by Src-poY416-specific antibodies and that is 
an appropriate surrogate marker for kinase activity in 
cells [53]. A limited set of studies has demonstrated a 
~2.5-fold increase in relative Src-poY416 staining in 
CR- vs. AD-CaP samples [20, 54], and in metastases 
(bone and lymph node) vs. primary tumor sites (Fig-
ure 2, unpublished data, Gary Gallick, MD Anderson 
Cancer Center). Taken together, these data strongly 
support a role for increased tyrosine kinase and SFK 
activity for progression to CR- and metastatic CaP.  
 
 
 
 
 
Figure 1. Relative expression level of Fyn in BPH, primary CaP (1º) and metastases 
(“Mets”) from Oncomine (http://www.oncomine.org) from the studies of Dhana-
sekaran et al. [116], Yu et al. [117], Varambally et al. [118] and Tomlins et al. [119]. 
 
Figure 2. Increased levels of activated Src in lymph node (LN) and bone metastases 
(BM) compared to primary-site (P) CaP. De-identified patient formalin-fixed paraffin 
sections from pathology archives (MD Anderson Cancer Center, under IACUC 
approval) were stained using Src-poY416-specific antibody (Cell Signaling Technolo-
gies, Inc., cat. # 201, 1:100, as described in [58]). Top images- Immunohistochemistry 
staining analysis for Src-poY416 in typical P, LN and BM clinical samples. Bottom panel- 
Scoring for relative Src-poY416 staining using the 0 to 3+ system, with the mean 
values shown as yellow lines. Published with permission from Gary E. Gallick, M.D. 
Anderson Cancer Center. 
 
In addition to the role of SFK in prostate cancer 
progression, several groups have reported that the 
non-receptor tyrosine kinase, Ack1 (Activated 
Cdc42-associated Kinase 1) may facilitate CaP pro-
gression through the direct activation of AR. Several 
mechanisms for Ack1 activation in prostate cancer 
have been identified, including gene amplification 
[55] or kinase hyperactivation [38] that occurs down-
stream of multiple receptor tyrosine kinases [56]. As 
shown in the study of Taylor et al. [57] (Figure 3), in-
creasing levels of Ack1 (TNK2) message are found in 
primary site CaP compared to normal or benign 
prostate hyperplasias (BPH), and even higher levels 
are found in lymph node metastases.  
Several lines of evidence indicate that the ex-
pression of specific SFK or Ack1 can drive the for-
mation of CaP or progression to CR-CaP. Although 
not the main focus of this review, there is a large body 
of evidence showing that SFK play key roles in facili-
tating proliferation of CaP induced by various growth 
factors and in promoting oncogenic migration pa-
rameters such as invasiveness [58] (reviewed in [32, 
59]). Indeed, Src is required for the lymph node me-
tastasis of a metastatic variant of PC-3 CaP cells alt-Int. J. Biol. Sci. 2014, Vol. 10 
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hough its knockdown has no effect on primary tumor 
growth [58]. Gelman et al. [60] recently demonstrated 
that TRAMP mice, whose prostate cancer progression 
is induced by the prostate-specific transgenic expres-
sion of the SV40 Tag [61], had greatly diminished 
prostatic adenocarcinoma and metastasis formation 
rates when crossed into Src-null, and to a lesser ex-
tent, Lyn-null backgrounds, but no change in the rate 
or extent of conversion to neuroendocrine cancer in 
the prostate. The loss of Fyn had no effect on primary 
tumor or metastasis formation in TRAMP mice ex-
hibiting CaP.  However, an interesting finding, and 
one that merits further investigation in the context of 
human disease, is that in rare cases where primary 
CaP failed to form within the typical onset period (<20 
weeks of age), the loss of Src, Lyn or Fyn resulted in 
highly aggressive metastatic disease exhibiting 
markers of adenocarcinoma. This might suggest that 
SFK suppress the growth of metastases in the absence 
of paracrine factors secreted by primary tumors, a 
phenomenon described in the TRAMP model [62] and 
in human cancers [63].  
 
 
Figure 3. Relative expression level of Ack1 (TNK2) in normal/BPH, primary CaP and 
lymph node metastases (mets) from Oncomine (http://www.oncomine.org) from the 
study of Taylor et al. [57]. 
 
The notion that activated Src is sufficient to drive 
CaP initiation comes from the study of Cai et al. [64] 
who used a tissue recombination model to show that 
Src, and to lesser extents, Fyn and Lyn, can induce 
prostatic basal epithelial cells to form CaP tumors 
when mixed with urogenital sinus mesenchymal cells. 
Subsequent phosphoproteome analyses of mouse 
tumors induced by activated AKT plus AR, ERG, or 
activated K-Ras, as well as of metastatic CR-CaP pa-
tient tumors, showed evidence of Src-driven path-
ways [31, 65]. Interestingly, even the overexpression 
of non-mutated c-Src was able to induce CaP initiation 
in the context of AR overexpression [66], an important 
finding given that Src kinase-activating mutations are 
not readily found in primary or CR-CaP  [67-69]. A 
recent paper by Su et al. [70] demonstrates that the 
frequency and time-to-onset of spontaneously gener-
ated CR-CaP in the CWR22 xenograft model are de-
creased by the siRNA-mediated knockdown of Src.  
Activation of AR by Direct Phosphoryla-
tion: Role of SFK and Ack1 
The landmark study by Guo et al. [20] demon-
strated that AR activation could be induced by direct 
phosphorylation by Src on Y534, as identified by mass 
spectrometry.  Kraus et al. [71]  confirmed that the 
Src-mediated tyrosine phosphorylation of AR was 
positively regulated by the PKC scaffolding protein, 
RACK1.  The concept that AR might serve as a Src 
substrate is strengthened by evidence that a Src-AR 
complex is required for androgen-induced CaP cell 
proliferation in vitro [72] and that Src kinase inhibition 
blocks AR-dependent transactivation of known an-
drogen-inducible genes [20, 73]. Moreover, expression 
of activated Src and the subsequent phosphorylation 
of AR on Y534 are sufficient to induce andro-
gen-independent growth in vitro  in LNCaP and 
LAPC-4 cells [38] and CR growth in vivo [20]. Acti-
vated Ack1 could also facilitate andro-
gen-independent CaP cell proliferation in vitro 
through the direct phosphorylation of AR on Y267 [38, 
74]. EGF treatment of LNCaP or LAPC-4 cells could 
induce AR phosphorylation on both Y267 and Y534, 
whereas other pro-proliferative stimulants could only 
activate AR through either Ack1 or Src pathways: 
AR-poY267 could be induced by heregulin or the Mer 
receptor ligand, Gas6, whereas AR-poY534 could be 
induced by IL-6 or bombesin [37].  Importantly, in-
creased AR-poY267 and -poY534 staining levels cor-
relate with CR-CaP disease progression and worse 
survival prognosis [20, 75], strongly suggesting that 
the increased activation of SFK and Ack1, and sub-
sequent AR activation through direct phosphoryla-
tion by these kinases, facilitates CaP malignancy, es-
pecially CR progression.  
Several non-genotropic AR functions have been 
described and are thought to occur at the plasma 
membrane, i.e.-  not through AR’s transactivation 
function  [76].  Interestingly, Src may controls these 
functions, which are poorly understood but which 
may regulate cell survival pathways, by direct bind-
ing to AR [77, 78]  although data are  lacking as to 
whether this control axis is dependent on Src phos-
phorylation of AR.  Int. J. Biol. Sci. 2014, Vol. 10 
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Tyrosine Kinase Antagonist Treatment in 
CR-CaP 
Studies corroborating the involvement of acti-
vated Src in progression to androgen-independence 
or castration-recurrence [70, 73, 79, 80], increased in-
vasiveness [66], or metastatic growth in bones [81], as 
well as preclinical studies demonstrating critical roles 
for SFK in prostate cancer metastasis [51, 58, 82-85] 
have spawned clinical trials using SFK-specific or 
pan-tyrosine  kinase inhibitors (reviewed in [2, 36]). 
  Indeed, a large set of review papers have ad-
dressed the rationale of targeting of SFK and Ack1 in 
CR-CaP, especially in its main manifestation as bone 
metastatic growths [36, 42, 43, 58, 86-90].  
 The effects of kinase inhibitors on CaP biology in 
vitro and in vivo depends, in most cases, on the speci-
ficity of the drugs studied.  For example, Dasatinib 
(BMS-354825), originally described as a 
Src/Abl-specific inhibitor [91], likely inhibits a wide 
range of receptor- and non-receptor tyrosine kinases 
[92]. Thus, whereas initial reports demonstrated that 
Dasatinib could inhibit Src/FAK-mediated signaling 
pathways that control prostate cancer cell adhesion, 
motility and invasiveness [50, 93], subsequent reports 
showed that it could also inhibit CaP growth as boney 
metastases  [94], androgen-independent growth [54] 
associated with the site-specific tyrosine phosphory-
lation of AR by Src or Ack1 [37], or spontaneous for-
mation of CR (CWR22) tumors [70]. Although early 
clinical trials showed some efficacy of using Dasatinib 
as a monotherapy or in combination with docetaxel 
[95-99], the recent READY Phase III trial showed that 
adding Dasatinib had no greater effect on survival in 
cases of chemotherapy-naïve metastatic CR-CaP [100]. 
Importantly, serum markers, such as insulin-like 
growth factor-1 (IGF-1), have been identified that 
correlate with efficacy by Dasatinib in metastatic 
CR-CaP cases [101], prompting a study by Dayyani et 
al.  [102]  showing superior inhibition of CR-CaP 
growths in mouse models when combining the 
IGF-1receptor/insulin-receptor inhibitor, 
BMS-754807, with Dasatinib.  
The argument that Dasatinib’s broad tyrosine 
kinase specificity undercuts its clinical efficacy [103] 
has resulted in the increased focus on more specific 
SFK inhibitors in CR-CaP.  For example, Saracatinib 
(AZD0530), a Src/Abl inhibitor which showed an-
ti-CaP efficacy in preclinical CaP models [104, 105] 
and in PC-3 bone metastases [106], showed efficacy as 
a monotherapy in CR-CaP patients [107].  Bosutinib 
(SKI-606) is another Src/Abl inhibitor [108] that has 
shown efficacy against prostate cancer in preclinical 
models [109], has passed Phase I testing [110] and was 
FDA-approved for use in Gleevec-resistant chronic 
myelogenous leukemia, yet is not part of any current 
Phase II trials for prostate cancer.  Cabozantinib 
(XL184), an inhibitor of the Met receptor tyrosine ki-
nase, which manifests its oncogenic signaling in 
prostate cancer through Src activation [83], has shown 
efficacy in Phase II trials against CR-CaP [111]. KXO1 
(KX2-391) is a novel non-ATP-competitive 
Src/tubulin polymerization inhibitor which, in recent 
Phase II studies [112], failed to reduce tumor burden 
in bone-metastasis CR-CaP cases, although a caveat 
noted was that the dosing was insufficient to achieve 
the drug’s tubulin polymerization inhibition activity. 
Lastly, several new Ack1-specific inhibitors have been 
identified [113], including AIM-100, which has shown 
efficacy against CR-CaP cell lines in vitro and in vivo 
[75, 114].  
Future Directions 
The growing corpus of evidence showing that 
SFK and Ack1 are potent drivers of CR-CaP and me-
tastasis via AR-dependent mechanisms has led to a 
renewed focus on developing specific tyrosine kinase 
inhibitors as mainline or adjunct therapies. In addi-
tion to solving issues of increased toxicities when 
combining such antagonists with newer generation 
inhibitors of AR or androgen synthesis, such as en-
zalutamide or abiraterone, respectively, there is no 
consensus  a priori as to whether SFK-specific drugs 
might work better than those with broad specificity 
for tyrosine kinases. As the use of SFK/Ack1 inhibi-
tors increases in CR-CaP populations, one area need-
ing improvement is the identification and develop-
ment of bio- or genetic markers of drug efficacy. One 
such example might be the development of immuno-
histochemistry-grade antibodies specific for 
AR-poY267 and –poY534. Indeed, newer pharmaco-
genetic  paradigms are being developed to identify 
individualized response and toxicity signatures that 
will help stratify patient-specific treatments [115] with 
the aim of improving patient survival outcomes. 
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